0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Sign in to save

Direct and Indirect Mitigation Strategies for Microplastic and Nanoplastic Exposure: A Conceptual Framework for Combination Therapeutic Development

Zenodo (CERN European Organization for Nuclear Research) 2026
Melinda B. Chu

Summary

Tiny plastic particles from our environment may contribute to inflammation, immune problems, and stress on our blood vessels and brain over time. This paper doesn't test new treatments but instead lays out a game plan for future research—combining strategies that reduce plastic buildup in the body with treatments that calm its downstream effects (like existing anti-inflammatory or heart-protective drugs). It's essentially a roadmap for scientists to start designing and testing real solutions, not proof that any treatment works yet.

Microplastics and nanoplastics (MPs/NPs) are emerging environmental exposure agents with potential relevance to inflammation, oxidative stress, immune dysregulation, endothelial dysfunction, neuroinflammation, and long-term healthspan. Therapeutic development in this area may require both direct mitigation strategies, aimed at reducing particle burden or interaction with tissues, and indirect mitigation strategies, aimed at modulating downstream biological consequences. This technical note outlines a conceptual framework for direct and indirect MP/NP mitigation, including possible combination approaches with existing anti-inflammatory, metabolic, neuroprotective, cardiovascular, and immunomodulatory therapies. The purpose is not to claim demonstrated clinical efficacy, but to define a translational strategy for future testing, partnership development, and resilience-focused therapeutic design.

Share this paper